The nitric oxide donor, V-PYRRONO, protects against acetaminophen-induced nephrotoxicity in mice

被引:45
作者
Li, CX
Liu, J
Saavedra, JE
Keefer, LK
Waalkes, MP
机构
[1] NIEHS, Inorgan Carcinogenesis Sect, Comparat Carcinogenesis Lab, NCI, Res Triangle Pk, NC 27706 USA
[2] SAIC Frederick, Frederick, MD USA
[3] NCI, Chem Sect, Comparat Carcinogenesis Lab, Frederick, MD 21701 USA
关键词
acetaminophen; renal pathology; nitric oxide; mice;
D O I
10.1016/S0300-483X(03)00129-X
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The nitric oxide (NO) donor, O-2-vinyl 1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate (V-PYRRO/NO), is metabolized by P450 enzymes to release NO in the liver and possibly other tissues. V-PYRRO/NO has been shown to be hepatoprotective, but little is known about its effect in the kidney, another organ rich in P450s. Thus, mice were given V-PYRRO/NO (0.4-5.4 mg/ml, 8 mul/h) before and/or after a nephrotoxic dose of acetaminophen (APAP; 600 mg/kg, i.p.) to examine its nephroprotective effects. V-PYRRO/NO administration significantly reduced APAP-induced nephrotoxicity in a dose- and time-dependent manner, as evidenced by mitigation of increased blood urea nitrogen levels and by amelioration of renal pathology, specifically interstitial congestion, proximal tubular cell degeneration and necrosis. The best protection was observed at the highest dose (5.4 mg/ml) and with V-PYRRO/NO pretreatment (4-16 h). Implanting V-PYRRO/NO pumps simultaneously with APAP also attenuated APAP nephrotoxicity. The protection is probably not due to a decreased APAP toxication metabolism, as similar depletion of renal glutathione levels was observed regardless of V-PYRRO/NO treatment. APAP-induced renal lipid peroxidation was reduced by V-PYRRO/NO, as determined by the concentrations of hydroxynonenals and malondialdehyde. In summary, this study demonstrates that the NO donor V-PYRRO/NO is effective in blocking APAP-induced nephrotoxicity in mice. The protection is probably due to multiple mechanisms involving attenuation of APAP-induced congestion and lipid peroxidation in the kidney. (C) 2003 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:173 / 180
页数:8
相关论文
共 24 条
  • [1] Protective effects of dietary L-arginine supplementation on chronic cyclosporine nephrotoxicity
    Andoh, TF
    Gardner, MP
    Bennett, WM
    [J]. TRANSPLANTATION, 1997, 64 (09) : 1236 - 1240
  • [2] L-arginine and allopurinol protect against cyclosporine nephrotoxicity
    Assis, SM
    Monteiro, JL
    Seguro, AC
    [J]. TRANSPLANTATION, 1997, 63 (08) : 1070 - 1073
  • [3] BLAKELY P, 1995, J AM SOC NEPHROL, V6, P48
  • [4] CARPENTER HM, 1981, J PHARMACOL EXP THER, V218, P161
  • [5] Eguia L, 1997, PHARMACOTHERAPY, V17, P363
  • [6] RETRACTED: A NO-releasing derivative of acetaminophen spares the liver by acting at several checkpoints in the Fas pathway (Retracted article. See vol. 156, pg. 868, 2009)
    Fiorucci, S
    Antonelli, E
    Mencarelli, A
    Palazzetti, B
    Alvarez-Miller, L
    Muscara, M
    del Soldato, P
    Sanpaolo, L
    Wallace, JL
    Morelli, A
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2002, 135 (03) : 589 - 599
  • [7] Diazeniumdiolates: Pro- and antioxidant applications of the "NONOates"
    Fitzhugh, AL
    Keefer, LK
    [J]. FREE RADICAL BIOLOGY AND MEDICINE, 2000, 28 (10) : 1463 - 1469
  • [8] Hart SGE, 1996, TOXICOL APPL PHARM, V136, P161
  • [9] ACETAMINOPHEN NEPHROTOXICITY IN CD-1 MICE .1. EVIDENCE OF A ROLE FOR IN-SITU ACTIVATION IN SELECTIVE COVALENT BINDING AND TOXICITY
    HART, SGE
    BEIERSCHMITT, WP
    WYAND, DS
    KHAIRALLAH, EA
    COHEN, SD
    [J]. TOXICOLOGY AND APPLIED PHARMACOLOGY, 1994, 126 (02) : 267 - 275
  • [10] HJELLE JJ, 1986, J PHARMACOL EXP THER, V236, P526